ABSTRACT
Objective To discuss the value of dual-input perfusion of 320 row CT on the efficacy evaluation of small cell lung cancer (SCLC).Methods A total of 18 patients with SCLC confirmed by pathology who received cisplatin plus etoposide chemotherapy between June 2016 and June 2018 in the 8th Medical Center of Chinese PLA General Hospital were collected.All patients received 320 row CT perfusion scan at 3 time points before chemotherapy,after 2 cycles and 4 cycles of chemotherapy.Tumor size,perfusion pseudo color map and bronchial arterial blood flow (BF),pulmonary flow (PF) and perfusion index (PI) were obtained.The efficacy and adverse reactions were evaluated.The single factor analysis was used to make the group comparison.Pearson test was used to make correlation analysis.Results Two patients after 2 cycles of chemotherapy had complete remission (CR),another 2 patients after 4 cycles of chemotherapy had CR,and 3 patients of the above 4 cases with CR had abundant BF;after 4 cycles of chemotherapy,7 cases had partial remission (PR),6 cases had stable disease (SD),1 patient had progression of disease (PD).Dual-input perfusion of 320 row CT showed that 10 cases had the tumor area ＜ 15 cm2 and 8 cased had the tumor area ＞15 cm2 before the treatment.There was a negative correlation between PI and the tumor area (r =-0.694,P =0.026) on patients with the tumor area ＜ 15 cm2 before the treatment,and no correlation was found in patients with tumor area ＞15 cm2 (P ＞ 0.05).One case had Ⅳ degree of bone marrow suppression,and obvious adverse reactions were not seen in the rest of the patients.Conclusion Dual-input perfusion of 320 row CT based on the simple imaging can make an accurate quantitative judgement of the effect of SCLC according to perfusion parameter,which provides a new basis for curative effect evaluation on SCLC.
ABSTRACT
Objective To analyze the clinical efficacy and safety of tegafur combined with oxaliplatin and gemcitabine combined with cisplatin in the treatment of advanced triple negative breast cancer.Methods Seventy-eight female patients with metastatic triple negative breast cancer who has afailed treatment with anthracycline/taxanes from January 1,2012 to December 31,2015 in PLA 309 Hospital were randomly divided into SOX group (38 cases) and GP group (40 cases) by computer generated random numbers.Results The objective response rates of SOX group and GP group were 31.5％ (12/38) and 32.5％ (13/40),and the disease control rates were 65.8％ (25/38) and 70.0％ (28/40),respectively.There was no significant difference between the two groups (P value was 1.000 and 0.809).The median progression-free survival time of GP group and SOX group was 6.6 and 5.5 months respectively,and there was a significant difference between the two groups (P=0.044).Adverse reactions in both groups included bone marrow suppression,gastrointestinal reactions and so on.The incidence rate of digestive tract reaction was 23.7％ (9/38) in SOX group and 27.5％ (11/40) in GP group.There was no significant difference between the two groups (P=0.699).The incidence rate of bone marrow suppression was 28.9％ (11/38) and 30.0％ (12/40),respectively.There was no significant difference between the two groups (P =0.920).Conclusion Tegafur combined with oxaliplatin and gemcitabine combined with cisplatin are effective drugs for the treatment of metastatic triple negative breast cancer,and the adverse reactions are tolerable.
ABSTRACT
<p><b>BACKGROUND</b>To observe the efficacy and safety of navelbine (NVB) combined with ifosfamide (IFO) and cisplatin (DDP) (NIP regimen) and IFO plus DDP (IP regimen) for advanced non-small cell lung cancer (NSCLC).</p><p><b>METHODS</b>One hundred and twenty patients with advanced NSCLC pathologically proved were randomly divided into group A (NIP regimen, n=60) and group B (IP regimen, n=60).</p><p><b>RESULTS</b>In group A, 58 patients were evaluable. The response rates were 58.62%(34/58), 65.58%(17/26) and 53.12% (17/32) in whole group, untreated patients, and retreated patients, respectively. The median duration of survival was 11.3 months. One-year survival rate was 40.0%. In group B, 59 patients could be evaluated. The response rates were 40.68%(24/59), 63.33%(19/30) and 17.24%(5/29) in whole group, untreated patients, and retreated patients, respectively. The median duration of survival was 9 months and 1-year survival rate was 36.7%. There was no significant difference in objective response rate among all the patients and the patients with no prior treatment between the two groups ( P > 0.05, P > 0.05). However, among retreated patients, the response rate in group A was remarkably higher than that in group B ( P < 0.05). The main dose limiting toxicity was myelosuppression. Leukopenia at grade III+IV was significantly higher in the NIP arm than in the IP arm ( P < 0.05).</p><p><b>CONCLUSIONS</b>NIP yields a higher response rate than IP does in retreated patients, with acceptable toxicity, which can be the first line regimen in the retreatment of advanced NSCLC. IP regimen showes a similar response rate and less toxicity in initial patients, compared with NIP regimen, so it might be considered a relevant regimen in initial patients with advanced NSCLC.</p>
ABSTRACT
OBJECTIVE:To evaluate the therapeutic efficacy and safety of MS Contin for patients with cancerous pain. METHODS:To control open clinical test was performed on 856 patients with terminal cancer,the analgesia effects,life quality and adverse reactions in these patients were compared before and after treatment with MS Contin.RESULTS:In the efficacy analysis,MS Contin lowered the pain degree(P